ArticleJournal of molecular histology2026
Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS), a major cause of female infertility, is accompanied by elevated anti-Mullerian hormone (AMH), ovarian hypervascularity, and excessive collagen deposition. While metformin is a well-established treatment, no study has yet explored whether Foeniculum vulgare (Fennel)-a medicinal plant with documented anti-PCOS benefits, administered alone or in combination-can attenuate these hormonal and structural abnormalities; this study provides the first integrated evaluation of both agents on ovarian damage in rats. Thirty-three female Wistar adult rats were divided into control and letrozole-induced PCOS groups. PCOS rats received saline (1 ml/kg/day; PCOS-Veh), fennel extract (500 mg/kg/day), metformin (300 mg/kg/day), or both for 21 days (n = 5/group). Body and ovarian weights were recorded, and blood samples were analyzed for AMH levels. Ovarian folliculogenesis, fibrosis, and vessel density were assessed by hematoxylin and eosin, and Masson's trichrome staining, and ovarian AMH expression by Western blot. PCOS rats exhibited fewer corpus luteum and pre-ovulatory follicles, more ovarian cysts, and increased fibrosis, vascularity, and AMH levels compared to the control. Fennel and metformin, particularly in combination, ameliorated ovarian histopathology by improving follicular abnormalities, increasing corpus luteum and pre-ovulatory follicles, and reducing cysts, fibrosis, hypervascularity, and ovarian dimensions. They also significantly lowered serum and ovarian AMH, with combination therapy being the most effective. These findings position fennel-particularly as an adjunct to metformin-as a dual modulator of both hormonal (AMH) and structural (vascular and fibrotic) ovarian alterations in a rat model of PCOS, although clinical trials remain essential before application in women with PCOS.
Indexed as
Identifiers
42831968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.